These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 15309697

  • 1. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure.
    Yoshizawa A, Yoshikawa T, Nakamura I, Satoh T, Moritani K, Suzuki M, Baba A, Iwanaga S, Mitamura H, Ogawa S.
    J Card Fail; 2004 Aug; 10(4):310-5. PubMed ID: 15309697
    [Abstract] [Full Text] [Related]

  • 2. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP, Wei CP, Ma SC, Zhang YF, Qiao LY, Li DH, Shan RB.
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [Abstract] [Full Text] [Related]

  • 3. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
    Fujimura M, Akaike M, Iwase T, Yoshida S, Sumitomo Y, Yagi S, Ikeda Y, Hashizume S, Aihara K, Nishiuchi T, Yasumura Y, Matsumoto T.
    Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure.
    Kataoka M, Satoh T, Yoshikawa T, Nakamura I, Kohno T, Yoshizawa A, Anzai T, Ogawa S.
    Circ J; 2008 Mar; 72(3):358-63. PubMed ID: 18296829
    [Abstract] [Full Text] [Related]

  • 5. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS.
    J Am Coll Cardiol; 2010 Apr 27; 55(17):1780-7. PubMed ID: 20413026
    [Abstract] [Full Text] [Related]

  • 6. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K, Norton GR, Kone N, Candy G, Kachope J, Woodiwiss AJ, Libhaber C, Sareli P, Essop R.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1825-30. PubMed ID: 15519014
    [Abstract] [Full Text] [Related]

  • 7. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
    Gundogdu F, Bozkurt E, Kiziltunc A, Sevimli S, Arslan S, Gurlertop Y, Senocak H, Karakelleoglu S.
    Echocardiography; 2007 Feb 02; 24(2):113-7. PubMed ID: 17313541
    [Abstract] [Full Text] [Related]

  • 8. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment.
    Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M.
    Am Heart J; 2001 Jun 02; 141(6):925-32. PubMed ID: 11376305
    [Abstract] [Full Text] [Related]

  • 9. Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
    Kojima M, Sato K, Kimura G, Ueda R, Dohi Y.
    J Cardiovasc Pharmacol; 2007 Apr 02; 49(4):191-6. PubMed ID: 17438403
    [Abstract] [Full Text] [Related]

  • 10. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
    Kallistratos MS, Dritsas A, Laoutaris ID, Cokkinos DV.
    Angiology; 2008 Apr 02; 59(3):323-8. PubMed ID: 18388105
    [Abstract] [Full Text] [Related]

  • 11. A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure.
    Nagatomo Y, Yoshikawa T, Kohno T, Yoshizawa A, Baba A, Anzai T, Meguro T, Satoh T, Ogawa S.
    J Card Fail; 2009 Apr 02; 15(3):224-32. PubMed ID: 19327624
    [Abstract] [Full Text] [Related]

  • 12. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
    Olsson LG, Swedberg K, Cleland JG, Spark PA, Komajda M, Metra M, Torp-Pedersen C, Remme WJ, Scherhag A, Poole-Wilson P, COMET Investigators.
    Eur J Heart Fail; 2007 Aug 02; 9(8):795-801. PubMed ID: 17693380
    [Abstract] [Full Text] [Related]

  • 13. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol.
    Sanderson JE, Chan SK, Yip G, Yeung LY, Chan KW, Raymond K, Woo KS.
    J Am Coll Cardiol; 1999 Nov 01; 34(5):1522-8. PubMed ID: 10551702
    [Abstract] [Full Text] [Related]

  • 14. The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
    Khand AU, Chew PG, Douglas H, Jones J, Jan A, Cleland JG.
    Cardiology; 2015 Nov 01; 130(3):153-8. PubMed ID: 25660493
    [Abstract] [Full Text] [Related]

  • 15. [The changes of plasma levels of brain natriuretic peptides in evaluation of treatment responses in chronic heart failure].
    Song JP, Shen B, Liu ZH, Jiang WP.
    Zhonghua Nei Ke Za Zhi; 2003 May 01; 42(5):306-8. PubMed ID: 12882709
    [Abstract] [Full Text] [Related]

  • 16. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
    Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC.
    Am Heart J; 2005 Mar 01; 149(3):541-7. PubMed ID: 15864245
    [Abstract] [Full Text] [Related]

  • 17. [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
    Wang F, Xu ZM, Wang L, Bian WY, Jia X, Duan B, Li W, Li YS.
    Zhonghua Nei Ke Za Zhi; 2005 Jul 01; 44(7):490-4. PubMed ID: 16080835
    [Abstract] [Full Text] [Related]

  • 18. Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.
    Susa T, Kobayashi S, Tanaka T, Murakami W, Akashi S, Kunitsugu I, Okuda S, Doi M, Wada Y, Nao T, Yamada J, Ueyama T, Okamura T, Yano M, Matsuzaki M.
    Circ J; 2012 Jul 01; 76(1):117-26. PubMed ID: 22008315
    [Abstract] [Full Text] [Related]

  • 19. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
    Takeda Y, Fukutomi T, Suzuki S, Yamamoto K, Ogata M, Kondo H, Sugiura M, Shigeyama J, Itoh M.
    Am J Cardiol; 2004 Aug 15; 94(4):448-53. PubMed ID: 15325927
    [Abstract] [Full Text] [Related]

  • 20. Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol.
    Arslan S, Erol MK, Bozkurt E, Acikel M, Gundogdu F, Atesal S, Senocak H.
    Int J Cardiovasc Imaging; 2007 Oct 15; 23(5):549-55. PubMed ID: 17171429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.